Remember that childhood excitement the night before Christmas?

Too excited to sleep, knowing something you wished for was finally within reach?

That’s exactly the spirit fueling our teams in Lyon as we approach the end of June. We’re eagerly awaiting the arrival of a powerful new platform at our European bioanalytical site, a new “toy,” but one designed to advance serious science.

So, what’s on its way to our Lyon facility?

We’re expanding our capabilities with a next-generation ligand-binding assay (LBA) platform specifically engineered for the most demanding biomarker studies.

If your project requires a technology that can:

  • Screen a broad panel of biomarkers in immunology and neurology
  • Detect ultralow concentrations of specific proteins
  • Support method development for complex or novel targets
  • Deliver a wide dynamic range with low variability
  • Perform reliably in complex biological matrices
  • Operate with minimal sample volumes

— then this new platform is exactly what your project needs.

The NULISA™ platform from Alamar Biosciences

We’re happy to announce that the technology joining our LBA suite is the ARGO™ HT System using the NULISA™ Technology, a cutting-edge platform from Alamar Biosciences.

The NULISA™ platform is a proteomic analysis system that enables attomolar-level sensitivity for protein biomarker detection and quantification. It combines a sequential immunocomplex capture-and-release mechanism with Next-Generation Sequencing (NGS) or qPCR as the readout method. This innovative approach bridges the precision of traditional immunoassays with the sensitivity of molecular biology, making it ideal for applications where every picogram counts.

Purpose-Built for Complex Biomarker Challenges

This platform brings significant advantages to drug development programs in neuroscience, infectious diseases, and inflammatory conditions, where detecting low-abundance biomarkers is often critical. Its efficiency with low sample volumes, along with multiplexing capabilities when needed, makes it particularly well-suited for early-phase and translational research involving scarce or precious clinical samples.

As the demand for ultra-sensitive biomarker detection continues to grow, we’re thrilled to be one of the few CROs globally to offer NULISA™, a powerful tool that further expands our spectrum of LBA capabilities and our ability to support complex biomarker programs with leading-edge technology.

Stay tuned for case studies and real-world applications as we begin leveraging this powerful new platform.